Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers examined outcomes among a group of people in middle- and low-income nations who switched to the integrase inhibitor.
Women in a global study began an HIV treatment regimen based on one of the two drugs after 20 weeks of gestation.
Tivicay was associated with a higher rate of viral suppression at delivery compared with Sustiva.
The antiretroviral GS-6207 is injected under the skin and would need to be combined with other meds to fully suppress HIV.
More high-quality evidence is needed to determine how this class of HIV medications may affect weight gain.
A large ongoing study in Botswana has found that about 1 in 150 babies exposed to Tivicay at conception developed such birth defects.
In a recent study, Edurant was better tolerated and less toxic and led to fewer discontinuations.
Various other studies have indeed found such a link.
Sustiva was connected to a 3.3-fold greater risk of suicidal behaviors in a new analysis.
Most of such drug resistance seen is to older drugs.
The tablet contains the same combo as Symfi Lo (efavirenz/lamivudine/tenofovir disoproxil fumarate) but with a higher dose of efavirenz.
This finding comes from an analysis of the global START study, which proved in 2015 that starting HIV treatment early is best.
Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston
After a gay man tested HIV positive, a test of his hair indicated he’d adhered well to PrEP—but did he contract a drug-resistant strain?
Investigators behind the recent study that raised this concern suggest not combining the two until more research can be done.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.